Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01797107
Other study ID # 40958
Secondary ID
Status Withdrawn
Phase Phase 2
First received January 30, 2013
Last updated September 27, 2016
Start date March 2013
Est. completion date July 2014

Study information

Verified date April 2015
Source Philadelphia Eye Associates
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of Azasite on patients with corneal surface irregularity (meibomian gland dysfunction).


Description:

This will be a single-center, randomized, vehicle-controlled, double-masked, clinical trial comparing a four week course of Azasite (azithromycin ophthalmic 1%) to vehicle (Durasite®) in patients with MGD-related evaporative dry eye. All patients will be evaluated at screening, baseline, two weeks, four weeks, and six weeks.

The primary outcome measure will be improvement, as compared to baseline, in corneal irregularity as measured by a topographically-derived value, the Corneal Irregularity Measurement (CIM). Secondary outcome measures will be a global symptom score, tear film break up time, meibomian gland secretion characteristics, best-corrected distance visual acuity, corneal staining, axial topography based astigmatism patterns, and IOL Master keratometry.

We will enroll 60 eyes of 30 patients, and each patient will be randomly assigned to receive Azasite in one eye and vehicle (Durasite®) in the fellow eye.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Ability to provide informed consent prior to enrollment in study

- Patient ability to follow study instructions and comply with all study protocols

- Corneal irregularity measurement (CIM) > 1.7 in both eyes

- Non-atrophic meibomian gland dysfunction (MGD) as defined by abnormal meibomian expression in at least 2 meibomian glands of the eyelids of each eye

- At least two symptoms of at least moderate severity (= grade 2, 0 to 3 scale) as defined in the MGD Global Symptom Score (Itching, Foreign-body sensation, Dryness, Burning, Lid swelling)

- Tear film break up time < 10 seconds

- Schirmer with anesthesia > 5 mm

- Best corrected distance visual acuity (BCDVA) > 20/100

Exclusion Criteria:

- Cicatricial or atrophic meibomian gland dysfunction (MGD)

- Any corneal disease or scar involving the central 6 mm, including epithelial basement membrane dystrophy, Salzmann nodular degeneration, recurrent erosions, keratoconus or ectasia

- Use of azithromycin or doxycycline within 1 month of screening

- Topical ocular antibiotic, anti-histamines, allergy, or steroid medication within 2 weeks of baseline (a 2 week washout after screening will be allowed)

- Topical prostaglandin analogue use within 30 days of study

- The anticipated use of any drops, gels or ointments during the study period outside of the study protocol

- Use of eye make-up during study period

- Active ocular infection or inflammation

- History of herpetic eye disease or neurotrophic keratitis

- Lid pathology (except MGD or blepharitis) that the examiner feels may affect the ocular surface

- Significant conjunctival scars (ex. h/o SJS)

- Pterygium

- Lacrimal punctal occlusion within 2 months of screening

- Ocular surgery within 1 year of screening

- Monocular patients

- Pregnant, breast-feeding, or sexually active females not using contraception

- Uncontrolled systemic disease

- Presence of any disease (medical or ocular) that, in the opinion of the investigator, may interfere with the study's safety or interpretation

- Known allergy to the study medication or its components

- Current enrollment in an investigational drug or device study within 30 days of screening for this study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Azasite
Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.

Locations

Country Name City State
United States Philadelphia Eye Associates Philadelphia Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Philadelphia Eye Associates Merck Sharp & Dohme Corp., Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Tear film break-up time Fluorescein break up time 2, 4 and 6 weeks No
Primary Change in Corneal Irregularity Measurement Topographically defined corneal smoothness as compared to baseline measurement at day 0 4 weeks No
Secondary Global symptoms score 0-3 score of itching, foreign body sensation, dryness, burning and swelling as compared to baseline measurement at day 0 2,4 and 6 weeks No
Secondary Meibomian gland secretion characteristics Meibum secretions of the eyelids will be assessed at each visit by pressing on the lower or upper lid (with a finger) until excretions are seen from at least 2 meibomian glands. The following scale, based on a scale in a study by Mathers et al (Mathers et al. Meibomian Gland Dysfunction in Chronic Blepharitis. Cornea .1991;10(4): 277-285.) will be used:
NE= <2 glands expressible = Atrophic or Cicatricial MGD (exclusion at Visit 1 and 2) 0= clear secretion (normal)
opaque secretion with normal viscosity
opaque secretion with increased viscosity
severely thickened secretion, toothpaste consistency At each time point, these characteristics will be compared to baseline at day 0.
2, 4 and 6 weeks No
Secondary Best corrected distance visual acuity as compared to baseline measurement at day 0 2, 4 and 6 weeks Yes
Secondary Corneal staining Using NEI industry workshop scale. Scores will be compared to baseline measurement at day 0 2, 4 and 6 weeks No
Secondary Axial topography based astigmatism pattern Patterns will be compared to baseline at day 0. All topography testing will be performed using the same machine and system, the Carl Zeiss Meditec Atlas, Model 9000, system 3.0.0.39.
The topographic pattern will be reviewed by a masked investigator (masked to eye randomization), and categorized as one of the following:
Normal/Symmetrical: Includes round, oval, or symmetric bowtie patterns
Asymmetric bowtie: Differentiated from symmetric bowtie by a difference between axial keratometry readings along the two lobes of >1D at points 1.5mm from the center, or a difference in the widths of the lobes of the bowties at that distance of >33%.
Irregular: Includes skewed radial axis (skewing by >20%), inferior or superior steepening (I-S asymmetry >1.2D); or a pattern that does not fit either 1 or 2 above.
2, 4 and 6 weeks No
Secondary Intraocular Lens(IOL) Master Keratometry As compared to baseline at day 0. 2, 4 and 6 weeks No
Secondary Change in Corneal Irregularity Measurement Topographically defined corneal smoothness as compared to baseline measurement at day 0 2 weeks, 6 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT04884243 - Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Terminated NCT02596919 - Fast Infrared Meibography (Photography) N/A
Completed NCT01207752 - The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction N/A
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT03652051 - A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED) Phase 2
Recruiting NCT03767530 - Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction N/A
Active, not recruiting NCT05577910 - Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD N/A
Completed NCT04889950 - Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction N/A
Recruiting NCT06004895 - Mechanisms of Light-based Therapies for Dry Eye Disease N/A
Completed NCT04147962 - Intense Pulsed Light in Meibomian Gland Dysfunctions
Completed NCT02256969 - Intraductal Meibomian Gland Probing Trial Phase 4
Recruiting NCT05089591 - Intense Pulsed Light in Meibomian Gland Dysfunction N/A
Completed NCT04500821 - Evaluation of the LipiFlow System With a New Activator N/A
Completed NCT03318874 - Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction Phase 4
Completed NCT06278584 - iLux Treatment for Meibomian Gland Dysfunction N/A
Recruiting NCT04052841 - Morphological Analysis of Meibomian Glands N/A
Completed NCT05028491 - The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients